INTRODUCTION
Allergic disease is very common in the United States, affecting approximately one third of the population. 1 Antigen avoidance, environmental controls, pharmacotherapy, and immunotherapy are often all required to alleviate symptoms. The impact on society and the health care system is significant. One analysis estimated $7.9 billion dollars per year is spent managing allergic disease. 2 Allergic rhinitis and asthma are the two leading causes of missed school days secondary to chronic illness. 3 Finally, quality of life is significantly affected, with allergic disease causing lower scores for social functioning, mental health, and energy/fatigue when compared with a control group. 4 Successful treatment of a chronic condition of this magnitude is paramount.
Effective immunotherapy may be derived from a variety of testing methods. The testing techniques available to the clinician have been evolving since the study of allergy and immunology began. In vitro testing has developed from radioallergosorbent test (RAST) to modified RAST to ImmunoCAP (Quest Diagnostics, Lyndhurst, NJ) methodology in an effort to improve sensitivity. Skin tests are preferred by many clinicians today because of the variable sensitivity of these assays compared with prick/ puncture skin tests, ranging from 50% to 90%. 5 In focusing on skin testing techniques, the options include scratch testing, skin prick testing (SPT), single intradermal testing, intradermal testing after SPT, and skin endpoint titration (SET), a type of intradermal dilutional testing (IDT). Regardless of the testing method chosen, an important factor for effective immunotherapy is to achieve high treatment doses that are close to the doses that cause large local or systemic reactions and to continue treatment at this level for long periods of time. 6 Some physicians refer to these doses as the maximally tolerated dose. Treatment at these levels produces several favorable immunologic changes, including a gradual increase in allergen specific immunoglobulin (Ig)G1 and IgG4 antibodies, increased IgM and IgA levels, declining allergen specific IgE levels, and down-regulation of basophil reactivity and sensitivity.
Otolaryngologists often favor IDT (SET) because of its well-documented sensitivity, specificity, safety, and reproducibility. IDT has been compared with many testing modalities used by other physicians to validate the technique as a part of mainstream allergy care. IDT has compared favorably with modified RAST. 7 Immunotherapy based on IDT results has been shown prospectively to be effective. 8 Several of the drawbacks to a pure IDT approach are the amount of time to perform the test, the cost, and the evaluation of fewer antigens. Despite the evidence of the efficacy of IDT, there are some clinicians who claim it is not an appropriate method of testing and suggest that SPT be used to determine clinically relevant allergy. 9, 10 Furthermore, there are some third-party payors who refuse to recognize IDT, describing it as experimental. Controversy persists regarding the correlation of SPT and IDT and the clinical relevance of IDT. Another fundamental question is whether there is value in determining the strongest safely administered starting dose for each individual antigen treated for each patient at the onset of immunotherapy. The present study compares the results of a screening multiple SPT device with IDT to determine the overall agreement of a positive result for each testing modality. In addition, the difference between the negative control and the positive antigen wheal measured during SPT was compared with the final IDT endpoint to determine any correlation. Finally, a comparison of the cost efficiency of each approach was performed.
Allergy Skin Testing: History and Current Controversy
Allergic reactions have been described as early as the writings of Hippocrates, but the first modern account of a patient with allergic rhinitis and asthma was written by Jonathan Bostock 11 in 1819 in an article entitled "A Case of Periodical Affection of the Eyes and Chest." In 1872, Wyman 12 determined ragweed pollen to be the cause of hayfever. The next year, Blackley performed the first allergy skin test by applying grass pollen to abraded forearm skin and noting a whealing response. 13 In 1911, an infectious disease physician named Leonard Noon 14 began to inject pollen extracts to try to cause patients to form a "pollen antitoxin" to diminish a patient's response to pollen exposure. He even introduced a definition of allergen potency, the "Noon unit," which is a weight/volume relationship. Comparison with modern methods of reporting allergen potency is as follows: 1 Noon unit ϭ 0.001 mg pollen ϭ .5 protein nitrogen unit ϭ 0.1 mL of #4 test solution. Scratch testing initially developed involving a drop of antigen placed on a superficial skin laceration. This technique has a reasonable safety profile but suffers from poor sensitivity and specificity. 15 In the 1920s, SPT was introduced. It enjoyed more widespread use in the 1970s with Pepys' 16 report detailing the technique. Since that time, multiple techniques are described by the term SPT. It is a qualitative method and has been found to potentially miss patients with lower level allergies. 17 Intradermal tests, the placement of a known quantity of antigen in the dermis, followed and were used in two very different ways. One was to verify negative results from SPT for patients who may have lower, clinically relevant allergies. The other is the use of multiple dilutions of the same antigens placed sequentially, known as SET or IDT. 18 The latter technique initially developed from the work of French Hansel, 19 an otolaryngologist who determined that using multiple dilutions of the same antigen yielded more useful information than use of a single dilution. This finding was consistent with and an extension of Phillips' 20 report that the safe dose of antigen to be given correlated with the size of the intradermal skin reaction to that concentration of antigen. In 1937, after working with Hansel, a general allergist named Herbert Rinkel 21 further defined the concept of SET. He supported the use of the 1:5 dilution technique because of its reproducibility and reliability as well as the amount of clinically relevant information, both qualitative and quantitative, that could be gleaned from this approach. This observation became one of the cornerstone concepts from which SET, a form of IDT, developed.
In today's health care environment, pressures to make care cost efficient as well as effective and safe are growing. SPT as a screening examination initially gained popularity as an added measure of safety because of concerns regarding individual SPTs and subsequent significant systemic reactions. 22 Furthermore, a large study confirmed the close relationship of skin test positivity using SPT and reported symptoms of nasal allergy in a general population (n ϭ 2,167 patients). 23 Despite the fact that false-positive skin test results did occur in a small subset of patients, there was a close relationship between SPT positivity, specific IgE, and symptoms of nasal allergy. The correlation between endpoint obtained from IDT and SPT positivity was not evaluated. One problem with prick testing of any variety is the number of variables that can affect results, including depth of the puncture needle and the force, duration, and angle of the application device. Another problem is that it is only a qualitative test, that is there is no way to determine whether the skin response is a false-negative or may represent an unusual response such as a flash response. In addition, there is significant concern about the reproducibility of allergy skin test scoring and interpretation when single prick devices are used. 24 In its Summary Statements of Practice Parameters for Allergy Diagnostic Tests, the American Academy of Allergy, Asthma, and Immunology (AAAAI) states it is impossible to quantify the exact amount of injected material by prick/puncture tests. 5 This statement may help to explain the findings of Tandy et al., 25 who did not find a good correlation with positive multiple skin prick device test results and modified RAST, whereas there was good correlation with comparative negative results. Despite these statements and findings, there are third-party payors whose only approved methods of skin testing for inhalant allergies are SPT and single intradermal tests. These payors have policies that state that prick and scratch tests are proven services for the evaluation and management of allergies, whereas SET is an unproven service because of inadequate evidence of safety or efficacy. To support this assertion, a list of allergy publications is supplied as a reference. Careful review of these studies is warranted. The most comprehensive references listed are position statements by the AAAAI regarding this topic. These position statements are again predicated on past studies. The 1993 position statement on allergen skin testing recommends prick testing as the initial allergy screen primarily because of logistical issues: it is easier to test more antigens in less time. 26 The 1995 summary statement from the AAAAI states that "for inhalant allergens, prick/puncture tests are generally felt to correlate better with the presence of clinical allergy." No reference is cited to specifically support this statement, and a review of the 316 reference bibliography reveals three papers that directly compare testing techniques. The first, a 1982 French study, compares three different prick tests, an intradermal test, and RAST results for dust mite allergy in a group of 30 patients. 27 Their conclusion was that the differences between prick tests and intradermal tests are not clearly understood. The second is a 1979 study looking at the correlation of Multi-Test and intracutaneous tests for immediate allergic reactions in a group of 20 patients. 28 There appeared to be an association between the results of these two techniques, but the study was limited by sample size. The third is a 1971 paper from the Netherlands comparing intracutaneous, scratch, and prick tests. 29 This paper is referenced in one AAAAI position statement to affirm that prick tests correlate better with clinically relevant allergy than IDT results. There were 26 patients, and two allergenic extracts were examined. Its primary stated purpose was actually to determine the allergen-extract concentration to be used to make the techniques comparable. The method used involved a statistical equation not designed for this purpose but instead to estimate the allergen content of an unknown extract by reference to a standard extract. This analysis is thus subject to debate because of use of this statistical method. In addition, careful reading of this paper reveals techniques that are not commonly used today. Modern multiple SPT devices were not available at the time of publication. Finally, there was not uniform standardization of allergenic extracts with regard to potency. To illustrate this problem, a paper from 1977 evaluated a group of 40 patients with a large total number of prick and scratch tests (n ϭ 2,395) and found clear differences in the potency of extract solutions from three large manufacturers of testing antigen. 30 Another issue is the safety of allergy testing techniques and resultant immunotherapy. Single intradermal tests not paired with SPT are very sensitive but have a greater potential to cause significant adverse reactions. 31 IDT was evaluated through a prospective, multicenter study that showed that serious reactions are uncommon. 32 This technique and its related immunotherapy have not been shown to have a higher risk of serious local or systemic reaction when comparing IDT with SPT. 15 IDT has been approved by the Allergy Panel of the American Medical Association Council of Scientific Affairs as being both useful and effective in the diagnosis of allergy. 33 SPT is also a safe and rapid means of skin testing. However, immunotherapy begun from SPT results must start at a very dilute level because the precise sensitivity of each antigen is unknown. 6 Because of this dilute initial immunotherapy, a much longer period is required to attain maintenance levels and thus desensitization. Attempts have been made to remedy this problem with the advent of rush immunotherapy. Rush immunotherapy has the same dose goals as traditional immunotherapy derived from SPT or IDT but with various forms of an accelerated interval between injections. 34 Regardless of the specific schedule, all rush immunotherapy approaches involve a higher risk of anaphylaxis. 6 Modern analysis in otolaryngic allergy studies has begun to suggest a complementary role for SPT and IDT for the effective and cost-efficient delivery of care for patients with allergy. A recent study showed that using a multiple SPT device as a screening examination versus IDT for screening (vertical safety screen) was nearly three times less expensive when examining the cost to the physician. 35 However, there has been some controversy regarding whether a multiple skin prick device is truly predictive of IDT results that are clinically relevant. This emanates from the fact that some clinicians use 1:10 dilutions instead of 1:5 dilutions. This means that the #1 dilution (1:10) correlates with the #2 dilution (1:5), the #2 dilution (1:10) is equivalent to a concentration between the #3 and #4 dilutions (1:5), and the #3 dilution (1:10) correlates with the #5 dilution (1:5) when comparing single intradermal with initial skin prick versus IDT. 36 Some clinicians using 1:10 dilutions believe that #2 (1:5) and even #3 (1:5) dilutions are not clinically relevant. More modern studies do not support this view. A recent study showed that IDT compared favorably with both SPT and nasal provocation testing (NPT). In fact, there was no statistically significant difference in the positive or negative predictive value between IDT and SPT. 37 This paper is especially significant because it uses a third technique, NPT, as a means to compare IDT and SPT. One of the limitations of this study was the sample size (n ϭ 62), but the study was powered to be able to show equivalency between the testing techniques. More recently, SPT, using the Multi-Test II device, and IDT were compared directly. 38 IDT was found to be more sensitive than SPT for low-level allergies. There was a poor correlation between SPT score and IDT endpoint. Although a correlation may be statistically significant, a Spearman correlation coefficient of 0.37 may not be strong enough to be useful. More direct clinical comparisons will help to further define this issue.
MATERIALS AND METHODS
Retrospective comparison of 134 patients with a history and physical findings suggestive of inhalant allergy who underwent SPT followed by IDT was performed in a multiple-physician, single-specialty otolaryngology private practice between January 2003 and May 2005. After exemption status was granted by our regional institutional review board, study recruitment involved a report generated by our electronic medical records system for all patients who underwent SPT and IDT. Study recruitment involved mailing patients 305 packets that consisted of an introductory cover letter, an informed consent, and a Health Insurance Portability and Accountability Act (HIPAA) release. One hundred forty patients responded. Six patients were excluded from the study: four had prick testing with a different device, and two did not have the positive and negative controls recorded on their IDT. Each patient enrolled signed both an informed consent to use his or her data anonymously as well as an HIPAA release. All allergy test results evaluated in this study were completed per the regular allergy evaluation in our office. The population studied represented all patients referred for allergy testing and those patients with a history and physical examination consistent with allergic rhinitis, chronic sinusitis, or related comorbid conditions.
SPT was performed on test day 1 using the GreerTrack device (Greer Laboratories, Lenoir, NC), a multiple skin-prick testing device comparable with the Multi-Test II device (Lincoln Diagnostics Inc., Decatur, IL). Several representatives from Greer Laboratories visited to assure proper testing technique with the GreerTrack device. The panel used for SPT included 28 antigens chosen for their prevalence in the region or their lack of cross-reactivity (Table I) . Some recommend screening panels of 10 to 12 antigens on the basis of past studies using in vitro tests. 39 This study's panel was based on the geographic area involved and was compiled in an effort to limit cross-reactivity. 40 Standardized allergenic extracts from Greer Laboratories were used, and these were stored at 46°F. Each antigen chosen represented a different family within a group of inhalant allergens (i.e., lamb's quarters to represent the Chenopodaceae family within the weed group). Results were read after 20 minutes. To decrease subjectivity in documenting results, wheal response only was recorded in millimeters using the skin test reaction guide (Antigen Laboratories, Inc., Liberty, MO). Wheal growth 2 mm or greater than the glycerin/saline control was considered positive. A difference score for each antigen testing positive was determined by subtracting the wheal size (mm) of the glycerin/saline control from the antigen wheal size (mm). This difference score allowed identification of the degree of positivity of the SPT result in the context of each patient's skin reactivity to glycerin. IDT was performed on test day 2 and was based on the positive results from the patient's SPT. Antigens negative by SPT were not evaluated by IDT. Each day of testing, histamine and glycerin/saline controls were placed. Wheal response only was measured 10 minutes after IDT was administered. IDT endpoint was defined as a positive wheal enlarged at least 2 mm greater than the preceding negative wheal, followed by a confirmatory positive wheal demonstrating a pattern of progression of wheal size with increasing antigen concentration (at least 2 mm greater than the preceding positive wheal). 6 The lowest endpoint (highest concentration) determined in this manner was a #2 (1:500) endpoint. The histamine control measured greater than the glycerin/saline control for every patient. Because of concerns about standardization of source materials as well as the significance of skin test results for certain antigen classes, fungal antigens were also reviewed separately. 41, 42 Spearman's rank correlation coefficient was used to evaluate correlations between several variables of interest, principally the comparison between the IDT endpoint and the difference score for all antigens, for molds separately, and the size of the histamine and the glycerin/saline wheals. The Wilcoxon signed rank test was used on calculated paired difference scores of interest. Statistical analyses were performed with SAS statistical software, version 9.1 (SAS Institute, Inc., Cary, NC).
To compare cost efficiency, testing recommendations from both the American Academy of Otolaryngic Allergy (AAOA) and the AAAAI were reviewed. In addition, the testing regimens of several regional general allergy practices were determined. With use of 2004 Medicare rates for specific codes and number of units for each code based on Academy recommendations, internal data, and regional general allergy practice data, a comparison of the costs to the health care system was made. To illustrate the significance of length of immunotherapy, the cost of vial preparation and shot administration was compared for a 3, 5, and 7 year period.
RESULTS
There were 3,752 antigens evaluated by SPT in 134 patients. The study patients' average age was 43 years. Of these antigens, 1,334 (35.55%) tested positive. No significant local or systemic reactions occurred. The antigens testing positive by SPT were subsequently tested by IDT on a separate day. The average time interval between test sessions was 21 days. There was good agreement between positive SPT and IDT results. Of the 1,334 antigens, 1,245 (93.33%) had a definable endpoint determined by IDT. When molds were evaluated separately, similar results were found. Nine hundred thirty-eight mold evaluations were performed on 134 patients. Of these, 313 (33.37%) were positive by SPT. Of the 313 antigens, 301 (96.17%) had a definable endpoint determined by IDT. The average number of antigens with a treatable endpoint per patient was 9.3. The mean number of units per antigen required to determine the endpoint during IDT was 3.9. The definable endpoints determined in this study varied, with a range of a #2 to a # 9 endpoint (1:5 dilutions). The majority of endpoints were #4 or higher (less concentrated). The #2 endpoint represented 9% of all determined endpoints. When molds were evaluated separately, similar results were obtained, with the #2 endpoint accounting for 10% of all mold endpoints. The majority of mold endpoints were also #4 or higher. The next issue evaluated was the correlation between the positivity of the SPT result and the definable endpoint. To make this determination, a difference score was obtained for each antigen by subtracting the wheal size (mm) of the glycerin/saline control from the wheal size (mm) for each antigen that tested positive. These scores had a range of 2 to 20 mm. This difference score was then compared with that antigen's endpoint to determine any correlation. There was a low moderate to low correlation between these measures (Fig. 1) . The overall Spearman correlation coefficient between the difference score and IDT endpoint for all antigens was r ϭ 0.40 (P Ͻ .0001). When molds were separately evaluated, there was a similar level of correlation (Fig. 2) . The overall Spearman correlation coefficient between the difference score and IDT endpoint for mold antigens was r ϭ 0.34 (P Ͻ .0001). The antigens testing positive by SPT but with a negative IDT evaluation were also reviewed. Of the 89 antigens evaluated, 9 had a reaction during IDT, which did not allow determination of a treatment endpoint: 3 flash responses and 6 unusual patterns of wheal development. The number of antigens with absolutely no reaction was 80 of a possible 1,334. These antigens varied by class. Trees and epidermals each represented 27.5% of these IDT negative antigens, whereas weeds represented 25%. The difference scores varied, with the majority having a difference score of 2 mm (Fig. 3) . A cost analysis was determined using 2004 Medicare rates. Several testing algorithms were compared (Table II) . RAST was not included in the comparison because it is not the preferred method of testing by either the AAOA or the AAAAI. A pure IDT approach using 12 antigens was evaluated. A primarily SPT approach was evaluated using 60 antigens and 20 single intradermal tests. The method described in this paper was also evaluated, using SPT for 28 antigens and IDT for 9.3 antigens. All three approaches were similar in cost. Finally, the effect on health care costs of shortening a course of immunotherapy was examined (Table  III) . Shortening the course of immunotherapy saves the health care system at least $1,062 per patient per year.
DISCUSSION
Multiple skin prick devices, single intradermal tests, and IDT are the most commonly used skin testing techniques today for inhalant allergy. SPT devices continue to improve in design and performance. Older studies have compared older devices with other in vitro and skin testing techniques favorably. Per the AAAAI position statement, SPT correlates well with clinically relevant allergy. As new multiple skin prick devices have been introduced and evaluated, there is some variability between devices regarding a positive SPT result that is significant. This variability is caused by different device specifics (number of tines per test head, range of amount of antigen deliv- ered, depth of antigen delivery), and it makes it difficult to report on SPT without a comparison of the study device with other commonly used devices. The device used in this study was the GreerTrack multiple skin prick device from Greer Laboratories. Its design has compared favorably with other multiple skin prick devices. Important features include a larger footprint area, wider tine spacing, and more tray sites when compared with the Multi-Test II (Table IV) . The number of tines per test head is four as compared with nine for the Multi-Test II. The depth of skin penetration is the same at 2 mm. The range of the amount of antigen delivered is 3 to 7 L for the GreerTrack, and 5 to 10 L for Multi-Test II. Comparative performance of multiple prick skin test devices has had a somewhat limited review. One study in 1993 included the Multi-Test among others but did not include the more modern Multi-test II or the GreerTrack. 43 An important point from this review was the call for a reexamination of the dictum that a 3 mm wheal from prick testing represents a significant reaction. The size of a clinically relevant wheal must be determined for each device. In a 2004 letter to the editor, the same author compared multiheaded SPT devices, including the Multi-test II and GreerTrack. 44 There was no difference in subject discomfort, with none reported for the GreerTrack and MultiTest II. The GreerTrack device was noted to produce smaller reactions to histamine than some of the other devices and thus pseudo false-negative (6.2%) or false-negative (5.2%) reactions. Ninety-six histamine tests in 21 adult subjects were performed. Our experience with this device in 134 patients (134 histamine tests) did not parallel these findings. In our study, wheal only was measured, and histamine reactions were varied, with the median wheal size of 9.0 mm, varying from 7.0 to 13.0 mm. No false-negative or pseudo false-negative reactions to the histamine control were noted. The glycerin/saline wheal size was also reviewed, with a median wheal size of 5.0 mm, varying from 4.0 to 7.0 mm. There was a very low correlation between these measures (r ϭ 0.17), and the difference between the histamine and glycerin/saline wheals was highly significant (P Ͻ .0001). The difference from the other reported histamine data might be explained by the fact that the histamine result was read at 20 minutes (vs. 8 min). Because the positive and negative controls in this study were placed simultaneously with the antigens, all were read after the same time interval. Regardless of the histamine wheal size, one might predict that antigen wheal size may be smaller for the GreerTrack than the MultiTest II because there is a smaller range of antigen delivered by the GreerTrack device. This reinforces the fact that the size of a clinically relevant reaction must be determined for each device. A recent review of these devices supports this approach. 45 In this study, any SPT result (wheal only) 2 mm or greater than the negative control was considered significant. In addition, positive SPT results correlate well with the ability to determine a definable endpoint by IDT. Some believe that lower level (more concentrated) endpoints are not clinically relevant. This notion appears contradictory when one considers that IDT was only performed on antigens testing positive by SPT, by definition clinically relevant allergens. In addition, the majority of the determined endpoints were not low level, ranging from #4 (1:12,500) to #9 (1:39,062,500).
An area of contention is how to address the possibility of false-negative SPT results. In this study, negative SPT results were not further evaluated by intradermal testing. This approach is an assumption, and there is some disagreement in the literature on this topic. Several studies have evaluated this issue. Krouse et al. 46 showed that SPT has good predictive ability (87% sensitivity, 86% specific- SPT/Intradermal ϭ blended multiple skin prick and single intradermal testing; SPT/IDT ϭ blended multiple skin prick and intradermal dilutional testing; Vial preparation ϭ cost for one vial to be prepared (multiply by four for annual rate). ity) for timothy grass. In a separate study, Nelson et al., 9 evaluating timothy grass, found that a positive single intradermal skin test response in the presence of a negative SPT result did not indicate the presence of clinically significant sensitivity. The results for molds have not been as convincing, with poor sensitivity and specificity of SPT for Alternaria and modest improvement when further evaluating SPT negative tests with single intradermal tests. 42 There is controversy regarding which classes of antigens may have SPT negative results but clinically significant positive intradermal test results. 47 More work needs to be performed to more clearly determine which antigens deserve further evaluation when SPT results are negative.
In evaluating allergy skin testing techniques, another issue is translation of test results into effective immunotherapy. Although SPT is a good way to evaluate many antigens quickly, it is difficult to know with certainty at what antigen concentration to begin immunotherapy. Single intradermal tests are still performed and are useful. However, experience is required to begin this type of allergy testing, risk of a significant reaction is increased, and interpretation of results has been found to be unreliable. IDT is a thorough method of evaluating antigens and determining a safe starting dose for immunotherapy. The problem is its expense, the length of time to administer the test, and the limited number of antigens able to be evaluated because of the former two issues. Blended testing techniques have been performed for some time. Motivation for these approaches is varied and may include verification of negative results from another test (single intradermal test after SPT) or an effort to streamline the testing and treatment process. The current blended technique takes advantage of the strength of each of its components. Instead of 10 to 12 antigens, SPT screened 28 antigens in this study, whereas the average number of antigens treated by immunotherapy remained below 10. The size of the screening panel is important because of the lack of cross reactivity within many antigen classes. Although more time consuming and expensive, a limited IDT component in this testing protocol is cost competitive. IDT was used in a cost-effective manner to verify the SPT results and guide the inception of immunotherapy. It also allowed the beginning of immunotherapy that has a shorter buildup until maintenance doses are reached. This time (and thus cost) savings is demonstrated in the clinical practice guidelines for specific antigen immunotherapy. 48 Immunotherapy based on SPT alone typically starts at a concentration of 1:200,000 w/v. Immunotherapy based to some degree on IDT typically starts in the range of 1:12,500 to 1:62,500. There is a more gradual rise in antigen concentration during the buildup phase of immunotherapy based on IDT, with a resultant decreased likelihood of shot reactions delaying progression of therapy and a more rapid attainment of either the maximally tolerated dose or symptom relieving dose. This potentially results in a shorter duration of immunotherapy and thus a substantial cost savings.
A direct comparison reflecting costs to the health care system illustrates these issues. The AAAAI recommends up to 70 antigens for testing for inhalant allergy by SPT and also up to 40 single intradermal tests for inhalant allergy evaluation. In a poll of general allergy practices in our region (n ϭ 6), the number of antigens evaluated by SPT ranged from 50 to 99, with the average number being 60. The number of single intradermal tests chosen for this comparison (20 tests) was half of the AAAAI threshold. Our protocol uses SPT for 28 antigens, as previously described. Dividing the total number of treatable antigens by the number of study patients yielded 9.3 antigens as the average number treated. The mean number of units for each antigen evaluated by IDT in our practice was 3.9. With use of the units described above and 2004 Medicare rates, the various testing paradigms are cost competitive. Many have criticized using IDT because of its expense and because the information determined by IDT is eventually determined by continuing immunotherapy until a treatment endpoint is found, that is, until a concentration of an antigen is reached just below the concentration that causes a large local or systemic reaction. Even though testing regimens that include IDT are cost competitive, one must consider the complete picture of the cost to the health care system to understand the potential significant cost savings of using IDT to guide starting doses of immunotherapy. In looking at the cost of allergy injections and the cost of vial preparation, any decrease in the length of immunotherapy would be advantageous to both the patient and the health care system. The potential savings for this testing approach lies in the length of time immunotherapy is continued. Following the AAOA recommendations, our patients typically continue immunotherapy for 3 years and then taper off of shots. Each patient's needs are unique, and therapy must be tailored by their physician to meet those needs. This may mean a longer duration of immunotherapy for some patients. A recent study has shown that relief of allergy symptoms continues 3 to 4 years after stopping an immunotherapy regimen lasting 3 years. 49 Immunotherapy has also been shown to improve mucociliary clearance in as little as 1 year. 50 Immunotherapy begun after prick testing in our region often continues from 5 to 9 years or longer on the basis of information from practice polling. IDT allows a shorter buildup period until the maximally tolerated dose or the symptom relieving dose is determined. In addition, there is a more gradual rise in dose concentration during dose escalation, decreasing the possibility of local or regional reactions to injections slowing the buildup phase. Regimens using IDT have also been shown to rapidly cause changes in Ig and cytokine levels and improve quality of life scores. 51 By using a cost-effective testing algorithm that incorporates IDT to determine an antigen's endpoint, the effective immunotherapy dose is determined more rapidly, and the length of immunotherapy and thus the cost may be curtailed. Finally, this approach would appear safer because, although no significant reactions occurred during SPT or IDT testing, there was a poor correlation between the degree of positivity by SPT and the starting dose for immunotherapy determined by IDT.
CONCLUSION
Antigens that show reactivity to a multiple SPT device usually have a clinically relevant, treatable endpoint that is independent of the degree of positivity of the SPT result. IDT is an important step in determining the stron-gest starting dose for immunotherapy that may be safely administered. Starting immunotherapy in this manner may allow for a shorter duration of immunotherapy as compared with other testing techniques, with associated potential cost savings. The use of a relatively large screening panel is cost competitive and does not increase the average number of antigens treated by immunotherapy. Blended allergy testing techniques that include IDT in their protocol are safe and compare favorably with various single and blended techniques with respect to diagnostic accuracy and testing and treatment costs.
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